Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synthon Pexeva To Launch At 20% Discount To Generic Paxil; GSK Suit Settled

Executive Summary

Synthon will launch Pexeva (paroxetine mesylate) during the first half of the year at a 20% discount to generic versions of Paxil (paroxetine hydrochloride)

You may also be interested in...



Apotex Challenges FDA “Shared” Generic Exclusivity Policy In Paxil Suit

TorPharm is challenging FDA's policy of awarding "shared" 180-day marketing exclusivity to multiple generic companies

Paxil Generics Grab 65% Of New Scripts; Apotex May Sue Over Par/GSK Deal

Generics of GlaxoSmithKline's antidepressant Paxil have captured 65% of the market for new paroxetine prescriptions, Apotex said

Apotex Generic Paxil Priced At 7% Discount Following “At Risk” Launch

Apotex is relying on a district court ruling of noninfringement in launching the first generic of GlaxoSmithKline's antidepressant Paxil (paroxetine)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel